Compare Eli Lilly And Co (LLY) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Marqeta Inc — how do they compare? Eli Lilly And Co trades at $1,221.24 (market cap $1.08T), while Marqeta Inc trades at $15.56 (market cap $1.62B). The key difference: Eli Lilly And Co is far larger — about 666.7× Marqeta Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| LLY | MQ | |
|---|---|---|
Market Cap | $1.08T | $1.62B |
Sector | Health | Technology |
52-Week High | $1.24K | $26.00 |
52-Week Low | $639.43 | $15.04 |
Enterprise Value | $1.13T | $935.36M |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
MQ trades at $15.59, down slightly by 0.06%. The stock exhibits a bearish technical signal with strong selling pressure on moving averages. Fundamentally, the company shows improving revenue trends, with 2026 revenue projected at $677 million and a return to positive net income. Recent partnerships with Google and Riskified highlight strategic growth initiatives in digital payments and fraud prevention.
MQ's outlook is cautiously optimistic, driven by revenue growth and profitability improvements, but high valuation ratios and past earnings volatility present risks. Analyst consensus is a 'Hold' with a $19 price target, suggesting moderate upside potential from current levels amid competitive and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
